Recently, a 12-week randomized, double-blind, placebo-controlled clinical trial (NCT05006885) revealed that pemvidutide, a GLP-1/glucagon dual receptor agonist, may be an effective treatment for MASH, as pemvidutide treatment significantly reduced liver fat content, noninvasive biomarkers of liver inflammation, and body weight compared with placebo [188]. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.